Modus QA offers a range of cost-effective and innovative quality assurance tools for imaging, image guidance and radiotherapy.
With 2,600 QUASAR™ phantoms in clinical use worldwide, Modus Medical Devices Inc. is committed to assisting medical physicists and technologists in setting new standards in the field of medical imaging and radiation therapy.
Founded in 2000, Modus develops and manufactures sophisticated and cost-effective imaging technology and QA solutions such as the first commercial programmable respiratory motion phantom to reproduce patient breathing waveforms. Driven by scientific roots and continued strong ties to the scientific community, Modus strives to remain at the forefront of the complex and ever-evolving field of medical radiation technology. Both in-house expertise and collaborative relationships with clinical physicists and researchers allow Modus to fully support existing products and to speed the development of new concepts and ideas into market-ready devices.
As a manufacturer, Modus ensures its products are built to the highest standards in accordance with stringent principles of process control and continuous improvement. This commitment to quality is further reflected in the company’s strong after-sales customer service and technical support. From IGRT, IMRT, SRS quality assurance phantoms and optical CT scanners to fully automated workflow enhancing image analysis software, Modus products are built to provide you with confidence that every patient is receiving the best possible treatment.
Modus Medical Devices Inc. today released version 1.0.2 of its QUASAR™ Automated Delivery QA Software (ADQ) to improve radiation treatment planning QA. QUASAR™ ADQ automatically checks the machine log files generated for each session and performs a comparative analysis to the original planned distribution delivery.
Leading investigators around the world have been working on Magnetic Resonance Imaging Guided Radiation- Therapy (MRgRT) systems for the treatment simulation and daily patient setup verification of cancer patients in an effort to increase the accuracy and precision of image guided hypofraction targeting of tumours.